Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001193125-24-202168
Filing Date
2024-08-16
Accepted
2024-08-16 16:39:09
Documents
2

Document Format Files

Seq Description Document Type Size
1 424B3 d844290d424b3.htm 424B3 103520
2 GRAPHIC g844290g84a01.jpg GRAPHIC 51796
  Complete submission text file 0001193125-24-202168.txt   175947
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-281522 | Film No.: 241217227
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)